What was the overall market valuation of the US primary osteoarthritis market in 2024?

The overall market valuation was $1455.3 Million in 2024. Read More

What is the projected market valuation for the US primary osteoarthritis market by 2035?

The projected market valuation for 2035 is $3458.3 Million. Read More

What is the expected CAGR for the US primary osteoarthritis market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 8.19%. Read More

Which segment had the highest valuation in the US primary osteoarthritis market in 2024?

The knee osteoarthritis segment had the highest valuation at $600.0 Million in 2024. Read More

What are the projected valuations for the hand osteoarthritis segment by 2035?

The projected valuation for the hand osteoarthritis segment by 2035 is between $250.0 Million and $600.0 Million. Read More

How much is expected to be spent on medication for treating primary osteoarthritis by 2035?

Spending on medication for treating primary osteoarthritis is expected to reach between $600.0 Million and $1400.0 Million by 2035. Read More

What role do hospitals and clinics play in the US primary osteoarthritis market?

Hospitals and clinics accounted for a valuation of $600.0 Million in 2024 and are expected to remain a key end-user. Read More

Which company is a key player in the US primary osteoarthritis market?

Pfizer Inc is one of the key players in the US primary osteoarthritis market. Read More

What is the projected valuation for imaging as a diagnostic method by 2035?

The projected valuation for imaging as a diagnostic method by 2035 is between $500.0 Million and $1200.0 Million. Read More

What is the expected growth trend for therapies in the US primary osteoarthritis market?

The therapies segment is projected to grow to between $400.0 Million and $900.0 Million by 2035. Read More

US Primary Osteoarthritis Market

ID: MRFR/Pharma/15122-HCR

100 Pages

Satyendra Maurya

Last Updated: May 13, 2026

US Primary Osteoarthritis Market Research Report By Type (knee osteoarthritis, hand osteoarthritis, neck osteoarthritis, hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, shoulder osteoarthritis, others), By Diagnosis (imaging, joint fluid analysis, others, divided X-rays, Magnetic resonance imaging (MRI)), By Treatment (medication, therapies, surgery, others, analgesics, non-steroidal anti-inflammatory drugs, acetaminophen, duloxetine, aspirin, ibuprofen, naproxen sodium/ naproxen) and By End-user (hospitals & clinics, medical institutes, research organization, others) - Growth & Industry Forecast 2025 To 2035

US Primary Osteoarthritis Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Life Sciences, BY Type (USD Million) | |
  1. 4.1.1 knee osteoarthritis | |
  2. 4.1.2 hand osteoarthritis | |
  3. 4.1.3 neck osteoarthritis | |
  4. 4.1.4 hip osteoarthritis | |
  5. 4.1.5 wrist osteoarthritis | |
  6. 4.1.6 spinal osteoarthritis | |
  7. 4.1.7 shoulder osteoarthritis | |
  8. 4.1.8 others |
2. 4.2 Life Sciences, BY Diagnosis (USD Million) | |
  1. 4.2.1 imaging | |
  2. 4.2.2 joint fluid analysis | |
  3. 4.2.3 others |
3. 4.3 Life Sciences, BY Treatment (USD Million) | |
  1. 4.3.1 medication | |
  2. 4.3.2 therapies | |
  3. 4.3.3 surgery | |
  4. 4.3.4 others |
4. 4.4 Life Sciences, BY End-user (USD Million) | |
  1. 4.4.1 hospitals & clinics | |
  2. 4.4.2 medical institutes | |
  3. 4.4.3 research organization | |
  4. 4.4.4 others 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Life Sciences | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer Inc (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Johnson & Johnson (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Novartis AG (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AbbVie Inc (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Amgen Inc (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GlaxoSmithKline plc (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Eli Lilly and Company (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 US MARKET ANALYSIS BY TYPE |
6. 6.3 US MARKET ANALYSIS BY DIAGNOSIS |
7. 6.4 US MARKET ANALYSIS BY TREATMENT |
8. 6.5 US MARKET ANALYSIS BY END-USER |
9. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF LIFE SCIENCES |
12. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES |
14. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES |
15. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE) |
16. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million) |
17. 6.14 LIFE SCIENCES, BY DIAGNOSIS, 2024 (% SHARE) |
18. 6.15 LIFE SCIENCES, BY DIAGNOSIS, 2024 TO 2035 (USD Million) |
19. 6.16 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE) |
20. 6.17 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Million) |
21. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE) |
22. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million) | |
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million) | |
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

knee osteoarthritis
hand osteoarthritis
neck osteoarthritis
hip osteoarthritis
wrist osteoarthritis
spinal osteoarthritis
shoulder osteoarthritis
others

Life Sciences By Diagnosis (USD Million, 2025-2035)

imaging
joint fluid analysis
others

Life Sciences By Treatment (USD Million, 2025-2035)

medication
therapies
surgery
others

Life Sciences By End-user (USD Million, 2025-2035)

hospitals & clinics
medical institutes
research organization
others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓